Shernan G. Holtan

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

Shernan G. Holtan, Todd E. DeFor, Aleksandr Lazaryan et al. · Blood · 2015 · 482 citations · Full text

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

Javier Bolaños‐Meade, Mehdi Hamadani, Juan Wu et al. · New England Journal of Medicine · 2023 · 460 citations · Full text

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Javier Bolaños‐Meade, Ran Reshef, Raphael Fraser et al. · The Lancet Haematology · 2019 · 274 citations

Versus Tacrolimus, Transplantation, Immunosuppressive Therapy +9

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality

Margaret L. MacMillan, Marie Robin, Andrew C. Harris et al. · Biology of Blood and Marrow Transplantation · 2015 · 272 citations · Full text

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors

Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti et al. · Clinical Cancer Research · 2018 · 199 citations · Full text